Bracco Supports ASNC's Endorsement of Cardiac PET for Coronary Artery Disease Diagnosis
Bracco, a leader in diagnostic imaging, has expressed strong support for the American Society of Nuclear Cardiology's (ASNC) recent position statement. The ASNC recommends cardiac positron emission tomography (PET) with myocardial blood flow quantification as the preferred method for evaluating coronary artery disease (CAD). This endorsement is based on evidence that cardiac PET offers superior diagnostic accuracy and risk assessment compared to SPECT imaging, particularly in complex cases or patients with obesity. Bracco has been a proponent of this approach since 1989, facilitating its adoption by improving access and reimbursement, and investing in provider education. The company's cardiac PET portfolio includes Cardiogen-82 and HeartSee, which aid in assessing coronary defects and disease severity. 
